AMCP's Adam Colborn discusses survey findings on TrumpRx's six-month performance, examining payer skepticism about pricing claims and pharmacy access hurdles for patients.
Adam Colborn, JD
Advertisement
Adam Colborn is vice president of government affairs at AMCP.
Articles by Adam Colborn, JD
Adam Colborn explains why affordability and access aren't the same thing for TrumpRx, and how pharmacy participation gaps can leave patients stuck.
Colborn breaks down why most AMCP members don't see TrumpRx as the lowest price option, and what that means for MFN pricing claims.
AMCP's Adam Colborn breaks down survey findings on how health plans and PBMs view the TrumpRx platform.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Supply Chain Signal: How Policy Pressures Are Converging on Pharma
2
Why Temperature Control Is Now Pharma’s Make-or-Break Variable
3
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
4
Copeland Closes Dickson Deal to Expand Cold Chain Monitoring
5